240 related articles for article (PubMed ID: 8524214)
21. NDF/heregulin stimulates the phosphorylation of Her3/erbB3.
Kita YA; Barff J; Luo Y; Wen D; Brankow D; Hu S; Liu N; Prigent SA; Gullick WJ; Nicolson M
FEBS Lett; 1994 Jul; 349(1):139-43. PubMed ID: 8045292
[TBL] [Abstract][Full Text] [Related]
22. Neu differentiation factor inhibits EGF binding. A model for trans-regulation within the ErbB family of receptor tyrosine kinases.
Karunagaran D; Tzahar E; Liu N; Wen D; Yarden Y
J Biol Chem; 1995 Apr; 270(17):9982-90. PubMed ID: 7730382
[TBL] [Abstract][Full Text] [Related]
23. Heregulin activation of extracellular acidification in mammary carcinoma cells is associated with expression of HER2 and HER3.
Chan SD; Antoniucci DM; Fok KS; Alajoki ML; Harkins RN; Thompson SA; Wada HG
J Biol Chem; 1995 Sep; 270(38):22608-13. PubMed ID: 7673253
[TBL] [Abstract][Full Text] [Related]
24. Neu differentiation factor/neuregulin isoforms activate distinct receptor combinations.
Pinkas-Kramarski R; Shelly M; Glathe S; Ratzkin BJ; Yarden Y
J Biol Chem; 1996 Aug; 271(32):19029-32. PubMed ID: 8702572
[TBL] [Abstract][Full Text] [Related]
25. A Neu differentiation factor (NDF) domain essential for proliferation and alterations in morphology of colonic epithelial cells in vitro.
Whoriskey JS; Pekar SK; Elliott GS; Hara S; Liu N; Lenz DM; Zamborelli T; Mayer JP; Tarpley JE; Lacey DL; Ratzkin B; Yoshinaga SK
Growth Factors; 1998; 15(4):307-21. PubMed ID: 9714914
[TBL] [Abstract][Full Text] [Related]
26. Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin.
Sliwkowski MX; Schaefer G; Akita RW; Lofgren JA; Fitzpatrick VD; Nuijens A; Fendly BM; Cerione RA; Vandlen RL; Carraway KL
J Biol Chem; 1994 May; 269(20):14661-5. PubMed ID: 7514177
[TBL] [Abstract][Full Text] [Related]
27. Differential expression of NDF/neuregulin receptors ErbB-3 and ErbB-4 and involvement in inhibition of neuronal differentiation.
Pinkas-Kramarski R; Eilam R; Alroy I; Levkowitz G; Lonai P; Yarden Y
Oncogene; 1997 Dec; 15(23):2803-15. PubMed ID: 9419971
[TBL] [Abstract][Full Text] [Related]
28. Regulation of cyclooxygenase-2 pathway by HER2 receptor.
Vadlamudi R; Mandal M; Adam L; Steinbach G; Mendelsohn J; Kumar R
Oncogene; 1999 Jan; 18(2):305-14. PubMed ID: 9927187
[TBL] [Abstract][Full Text] [Related]
29. Binding of Neu differentiation factor with the extracellular domain of Her2 and Her3.
Horan T; Wen J; Arakawa T; Liu N; Brankow D; Hu S; Ratzkin B; Philo JS
J Biol Chem; 1995 Oct; 270(41):24604-8. PubMed ID: 7592681
[TBL] [Abstract][Full Text] [Related]
30. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling.
Graus-Porta D; Beerli RR; Daly JM; Hynes NE
EMBO J; 1997 Apr; 16(7):1647-55. PubMed ID: 9130710
[TBL] [Abstract][Full Text] [Related]
31. NDF/heregulins stimulate expression of the erbB-2 tyrosine kinase growth factor receptor gene in human breast cancer cells.
Maggiora P; De Bortoli M
Ann N Y Acad Sci; 1996 Apr; 784():443-7. PubMed ID: 8651595
[No Abstract] [Full Text] [Related]
32. Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3.
Wallasch C; Weiss FU; Niederfellner G; Jallal B; Issing W; Ullrich A
EMBO J; 1995 Sep; 14(17):4267-75. PubMed ID: 7556068
[TBL] [Abstract][Full Text] [Related]
33. The epidermal growth factor receptor couples transforming growth factor-alpha, heparin-binding epidermal growth factor-like factor, and amphiregulin to Neu, ErbB-3, and ErbB-4.
Riese DJ; Kim ED; Elenius K; Buckley S; Klagsbrun M; Plowman GD; Stern DF
J Biol Chem; 1996 Aug; 271(33):20047-52. PubMed ID: 8702723
[TBL] [Abstract][Full Text] [Related]
34. Phosphatidylinositol 3-kinase recruitment by p185erbB-2 and erbB-3 is potently induced by neu differentiation factor/heregulin during mitogenesis and is constitutively elevated in growth factor-independent breast carcinoma cells with c-erbB-2 gene amplification.
Ram TG; Ethier SP
Cell Growth Differ; 1996 May; 7(5):551-61. PubMed ID: 8732665
[TBL] [Abstract][Full Text] [Related]
35. Neu differentiation factor induces ErbB2 down-regulation and apoptosis of ErbB2-overexpressing breast tumor cells.
Daly JM; Jannot CB; Beerli RR; Graus-Porta D; Maurer FG; Hynes NE
Cancer Res; 1997 Sep; 57(17):3804-11. PubMed ID: 9288791
[TBL] [Abstract][Full Text] [Related]
36. NDF/heregulin-induced cell cycle changes and apoptosis in breast tumour cells: role of PI3 kinase and p38 MAP kinase pathways.
Daly JM; Olayioye MA; Wong AM; Neve R; Lane HA; Maurer FG; Hynes NE
Oncogene; 1999 Jun; 18(23):3440-51. PubMed ID: 10376522
[TBL] [Abstract][Full Text] [Related]
37. Heregulin-stimulated signaling in rat pheochromocytoma cells. Evidence for ErbB3 interactions with Neu/ErbB2 and p85.
Gamett DC; Greene T; Wagreich AR; Kim HH; Koland JG; Cerione RA
J Biol Chem; 1995 Aug; 270(32):19022-7. PubMed ID: 7642563
[TBL] [Abstract][Full Text] [Related]
38. NDF/heregulin activates MAP kinase and p70/p85 S6 kinase during proliferation or differentiation of mammary epithelial cells.
Marte BM; Graus-Porta D; Jeschke M; Fabbro D; Hynes NE; Taverna D
Oncogene; 1995 Jan; 10(1):167-75. PubMed ID: 7824269
[TBL] [Abstract][Full Text] [Related]
39. Heregulin induces increase in sensitivity of an erbB-2-overexpressing breast cancer cell type to lysis by lymphokine-activated killer cells.
Cardillo M; Yankelevich B; Mazumder A; Lupu R
Cancer Immunol Immunother; 1996 Sep; 43(1):19-25. PubMed ID: 8917631
[TBL] [Abstract][Full Text] [Related]
40. The oncogenic ErbB-2/ErbB-3 heterodimer is a surrogate receptor of the epidermal growth factor and betacellulin.
Pinkas-Kramarski R; Lenferink AE; Bacus SS; Lyass L; van de Poll ML; Klapper LN; Tzahar E; Sela M; van Zoelen EJ; Yarden Y
Oncogene; 1998 Mar; 16(10):1249-58. PubMed ID: 9546426
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
